Today: 21 May 2026
Browse Category

NSE:SWIGGY 12 December 2025 - 19 December 2025

NSE Adds Swiggy, Waaree Energies, Premier Energies and Bajaj Holdings to F&O From December 31: What Investors Need to Know

NSE Adds Swiggy, Waaree Energies, Premier Energies and Bajaj Holdings to F&O From December 31: What Investors Need to Know

Swiggy, Waaree Energies, Premier Energies, and Bajaj Holdings & Investment will join the NSE Futures & Options segment from December 31, 2025. The exchange will announce contract details, including lot sizes and strike prices, on December 30. NSE currently lists 208 single-stock derivatives. The additions coincide with a broader year-end reshuffle of eligible F&O stocks.
19 December 2025
····
Swiggy Share Price Today (14 Dec 2025): ₹10,000 Crore QIP Closes, Big Mutual Funds Buy In, Analyst Targets & Week-Ahead Outlook

Swiggy Share Price Today (14 Dec 2025): ₹10,000 Crore QIP Closes, Big Mutual Funds Buy In, Analyst Targets & Week-Ahead Outlook

Swiggy raised ₹10,000 crore through a Qualified Institutional Placement, pricing shares at ₹375, below the floor price. The QIP saw strong demand, with mutual funds taking a large share of allocations. Swiggy stock closed Friday at ₹416–₹417, up nearly 4% for the day but still below its November 2024 listing price. Markets were closed over the weekend.
14 December 2025
·
Swiggy Limited Share Price Today: Stock Rises on ₹10,000 Crore QIP Buzz, BofA Upgrade — Latest News, Targets, and Outlook (12 Dec 2025)

Swiggy Limited Share Price Today: Stock Rises on ₹10,000 Crore QIP Buzz, BofA Upgrade — Latest News, Targets, and Outlook (12 Dec 2025)

Swiggy shares rose about 4% to ₹417–₹420 on December 12, 2025, amid heavy trading after the company launched a ₹10,000 crore qualified institutional placement. Most QIP bids reportedly clustered near ₹375 per share, signaling a discount to the market price. The offer drew strong demand, with reports citing 4.5 times subscription from major investors. Swiggy set a floor price of ₹390.51 for the placement.
12 December 2025
··

Stock Market Today

  • Analyst Revises MongoDB Outlook After Sharp 22% Stock Decline
    May 20, 2026, 11:08 PM EDT. An analyst shifted to a more favorable view on MongoDB (NASDAQ: MDB) after its stock plunged 22% on March 3, 2026, despite better-than-expected fiscal Q4 results. The company reported $695 million revenue, up 27% year-over-year, with Atlas cloud revenue hitting a $2 billion annual run rate. However, cautious fiscal 2027 guidance projecting 16-18% revenue growth-below expectations-triggered the drop and a Baird price target cut from $500 to $260. The analyst now highlights MongoDB's strong business fundamentals, including a 23% adjusted operating margin and leading position in document databases, which support cloud-native applications. The initial high valuation and AI premium correction have shifted risk perceptions, revealing a steadier business amid recent market volatility.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop